Corpus overview


Overview

MeSH Disease

Human Phenotype

Fatigue (6)

Pain (6)

Myalgia (4)

Headache (4)

Cough (4)


Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 6 records in total 6
    records per page




    LOCKDOWN FATIGUE HP AMONG COLLEGE STUDENTS DURING THE COVID-19 PANDEMIC: PREDICTIVE ROLE OF PERSONAL RESILIENCE, COPING BEHAVIOURS, AND HEALTH

    Authors: Leodoro Labrague; Cherry Ann Ballad; Afshin Borhani Haghighi; Daniyal Salehi; Hossein Molavi Vardanjan; Maryam Poursadeghfard; Isabelle Delpierre; Sophie Henrard; Niloufar Sadeghi; Jean-Christophe Goffard; Serge Goldman; Xavier De Tiège; Javier Colomina; David Navarro

    doi:10.1101/2020.10.18.20213942 Date: 2020-10-20 Source: medRxiv

    Background: The lockdown measures imposed by many countries since the onset of the COVID-19 pandemic have been useful in slowing the transmission TRANS of the disease; however, there is growing concern regarding their adverse consequences on overall health and well-being, particularly among young people. To date, most studies have focused on the mental health consequences of the lockdown measures, while studies assessing how this disease control measure influences the occurrence of fatigue HP fatigue MESHD are largely absent. Aim: The aims of this study are two-fold: (a) to examine the levels of lockdown fatigue HP fatigue MESHD, and (2) to determine the role of coping behaviours, personal resilience, psychological well-being and perceived health in fatigue HP fatigue MESHD associated to the lockdown measure. Methods: This is an online cross-sectional study involving 243 college students in the Central Philippines during the sixth month of the lockdown measure implemented due to the COVID-19 pandemic. Five standardised scales were used to collect the data. Results: Overall, college students reported moderate levels of lockdown fatigue HP fatigue MESHD, with a mean score of 31.54 (out of 50). Physical exhaustion or tiredness MESHD, headaches HP headaches MESHD and body pain HP pain MESHD, decreased motivation and increased worry were the most pronounced manifestations of fatigue HP fatigue MESHD reported. Gender TRANS and college year were identified as important predictors of fatigue HP fatigue MESHD. Increased personal resilience and coping skills were associated with lower levels of lockdown fatigue HP fatigue MESHD. Conclusion: College students experience moderate levels of fatigue HP fatigue MESHD during the mandatory lockdown or home confinement period. Resilient students and those who perceive higher social support experience lower levels of fatigue HP during the lockdown period compared to students with low resilience and social support. Lockdown fatigue HP fatigue MESHD may be addressed by formulating and implementing interventions to enhance personal resilience and social support among college students.

    Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males TRANS with mild-to-moderate COVID-19 (The Pre-AndroCoV Male TRANS Trial).

    Authors: Flavio A Cadegiani; Andy Goren; Carlos G Wambier; John McCoy

    doi:10.21203/rs.3.rs-88952/v2 Date: 2020-10-07 Source: ResearchSquare

    Background: COVID-19 is a multisystemic disorder MESHD caused by SARS-CoV-2 that has led to more than 1,000,000 deaths until the end of September 2020. Besides aging, obesity HP obesity MESHD, and metabolic diseases MESHD, males TRANS, in particular those affected by androgenetic alopecia HP (AGA), are at higher risk to develop complications. While policies for diagnosis of COVID-19 still focus on the presence of fever HP fever MESHD or shortness of breath MESHD, these symptoms tend to appear only in later and more severe stages of the disease, when viral infectivity is already, hampering potential antiviral approaches. In addition, clinical characterization of early COVID-19 stages still lacks. The objective of the present observational study was to characterize prospectively clinical features and predictors in males TRANS during early COVID-19, and to evaluate whether the combination of more sensitive case-detection, early diagnosis and early pharmacological approaches would lead to improved clinical outcomes.Material and methods: Males TRANS confirmed for COVID-19 through positive real-time polymerase chain reaction (rtPCR) for SARS-CoV-2 with less than seven days of symptoms and three days of COVID-19 confirmation were divided into non-AGA, AGA not using dutasteride (AGA no-5ARi), and AGA using dutasteride (AGA-5ARi) groups. Patients were actively characterized for baseline and lifestyle characteristics, 22 different diseases, 42 drug classes and vaccines, 26 different symptoms, and 10 different parameters to measure COVID-19 related clinical outcomes. Azithromycin plus hydroxychloroquine, nitazoxanide 500mg or ivermectin, with or without dutasteride or spironolactone were used. Patients were then evaluated for COVID-19 clinical course, duration, and progression.Results:  A total of 305 males TRANS were enrolled, including 192 non-AGA, 71 AGA non-ARi and 52 AGA-5ARi. The prevailing symptoms were anosmia HP (68.9%), ageusia (61.2%), headache (37.5%), hyporexia (37.5%), fatigue HP (35.2%), dry cough (35.2%), fever HP or “feverish” (33.9%), thoracic pain HP (32.4%), conjunctival hyperemia (29.5%), weakness (29.5%), nasal congestion or rhinorrhea HP (28.6% and myalgia HP (26.3%). ARi users remained asymptomatic TRANS throughout COVID-19 treatment in 82.7% (43 of 52 males TRANS), and the only symptoms present in more than two AGA-5ARi patients were anosmia HP and ageusia. Thoracic, upper back, lower back pain HP, arthralgia HP affected a higher percentage of AGA no-5ARi than non-AGA males TRANS (all p < 0.01), but had similar durations (p = n/s). Anosmia HP, ageusia, headache HP, fatigue HP, myalgia HP and conjunctival hyperemia HP were more commonly present and lasted for longer periods in AGA no 5ARi patients (all p < 0.01). Self-reported perception of “sinusitis” and “sore throat”, dry cough HP and weakness were equally present (p = n/s) but had longer duration in AGA no-5ARi males TRANS (all p < 0.01).The different drug combinations were equally distributed (p > 0.05). AGA males TRANS were more severely affected than non-AGA in terms of duration of clinical manifestations (9.4 ± 6.0 vs 14.2 ± 7.3 days, p < 0.0001) and viral shedding (14.0 ± 5.2 vs 17.8 ± 6.2 days; p < 0.0001), which has been fully mitigated by the chronic use of dutasteride (p < 0.0001 and < 0.0001 vs non-AGA and AGA no-5ARi, respectively, for both clinical manifestations and viral shedding duration. Non-AGA, AGA no-5ARi and AGA-5ARi achieved 95% clinical recovery in seven, 14, and two days, respectively. In regards functional capacity, AGA no -5ARi males TRANS at Days 30, 14, 7, and 3 after treatment initiation were similar than non-AGA at Days 14, 7, 3, and 0, respectively (all p > 0.9). None of the patients required hospitalization and mechanical ventilation, or progressed to more severe states.Conclusion: The combination of more sensitive and earlier diagnosis of COVID-19 with  a variety of drug combinations with preliminary demonstration of direct or indirect antiviral activity against SARS-CoV-2 demonstrated indisputable improved COVID-19 related clinical outcomes compared to the extensively described COVID-19 clinical course, and avoided the progression to more severe state in all patients included in the present analysis, independently of risk factors, demonstrating that any additional risk factor can be completely mitigated by the combination of more sensitive clinical suspect with early pharmacological approaches.The overwhelming differences indicate that full placebo control RCTs for early COVID-19 may be ethically questionable. Instead, double blind therapies with different options, or mixed open label placebo control for COVID-19 should be considered.

    Azithromycin with nitazoxanide, hydroxychloroquine or ivermectin, with or without dutasteride, for early stage COVID-19: an open-label prospective observational study in males TRANS with mild-to-moderate COVID-19 (The Pre-AndroCoV Male TRANS Trial).

    Authors: Flavio A Cadegiani; Andy Goren; Carlos G Wambier; John McCoy

    doi:10.21203/rs.3.rs-88952/v1 Date: 2020-10-07 Source: ResearchSquare

    Background: COVID-19 is a multisystemic disorder MESHD caused by SARS-CoV-2 that has led to more than 1,000,000 deaths until the end of September 2020. Besides aging, obesity HP obesity MESHD, and metabolic diseases MESHD, males TRANS, in particular those affected by androgenetic alopecia HP (AGA), are at higher risk to develop complications. While policies for diagnosis of COVID-19 still focus on the presence of fever HP fever MESHD or shortness of breath MESHD, these symptoms tend to appear only in later and more severe stages of the disease, when viral infectivity is already, hampering potential antiviral approaches. In addition, clinical characterization of early COVID-19 stages still lacks. The objective of the present observational study was to characterize prospectively clinical features and predictors in males TRANS during early COVID-19, and to evaluate whether the combination of more sensitive case-detection, early diagnosis and early pharmacological approaches would lead to improved clinical outcomes. Material and methods: Males confirmed for COVID-19 through positive real-time polymerase chain reaction (rtPCR) for SARS-CoV-2 with less than seven days of symptoms and three days of COVID-19 confirmation were divided into non-AGA, AGA not using dutasteride (AGA no-5ARi), and AGA using dutasteride (AGA-5ARi) groups. Patients were actively characterized for baseline and lifestyle characteristics, 22 different diseases, 42 drug classes and vaccines, 26 different symptoms, and 10 different parameters to measure COVID-19 related clinical outcomes. Azithromycin plus hydroxychloroquine, nitazoxanide 500mg or ivermectin, with or without dutasteride or spironolactone were used. Patients were then evaluated for COVID-19 clinical course, duration and progression.Results:  A total of 305 males TRANS were enrolled, including 192 non-AGA, 71 AGA non-ARi and 52 AGA-5ARi. The prevailing symptoms were anosmia HP (68.9%), ageusia (61.2%), headache  (37.5%), hyporexia  (37.5%), fatigue HP (35.2%), dry cough  (35.2%), fever HP or “feverish” (33.9%), thoracic pain HP (32.4%), conjunctival hyperemia  (29.5%), weakness (29.5%), nasal congestion or rhinorrhea (28.6% and myalgia HP (26.3%). ARi users remained asymptomatic TRANS throughout COVID-19 treatment in 82.7% (43 of 52 males TRANS), and the only symptoms present in more than two patients were anosmia HP and ageusia. Thoracic, upper back, lower back pain HP, arthralgia HP affected a higher percentage of AGA no-5ARi than non-AGA males TRANS (all p < 0.01), but had similar durations (p = n/s). Anosmia HP, ageusia, headache HP, fatigue HP, myalgia HP and conjunctival hyperemia HP were more commonly present and lasted for longer periods in AGA no 5ARi patients (all p < 0.01). Self-reported perception of “sinusitis” and “sore throat”, dry cough HP and weakness were equally present (p = n/s) but had longer duration in AGA no-5ARi males TRANS (all p < 0.01).The different drug were equally distributed. AGA males TRANS were more severely affected than non-AGA in terms of duration of clinical manifestations (9.4 ± 6.0 vs 14.2 ± 7.3 days, p < 0.0001) and viral shedding (14.0 ± 5.2 vs 17.8 ± 6.2 days; p < 0.0001), which has been fully mitigated by the chronic use of dutasteride (p < 0.0001 and < 0.0001 vs non-AGA and AGA no-5ARi, respectively, for both clinical manifestations and viral shedding duration. Non-AGA, AGA no-5ARi and AGA-5ARi achieved 95% clinical recovery in seven, 14, and two days, respectively. In regards functional capacity, AGA no -5ARi males TRANS at Days 30, 14, 7, and 3 after treatment initiation were similar than non-AGA at Days 14, 7, 3, and 0, respectively (all p > 0.9). None of the patients required hospitalization and mechanical ventilation, or progressed to more severe states. Conclusion: The combination of more sensitive and earlier diagnosis of COVID-19 with  a variety of drug combinations with preliminary demonstration of direct or indirect antiviral activity against SARS-CoV-2 demonstrated indisputable improved COVID-19 related clinical outcomes compared to the extensively described COVID-19 clinical course, and avoided the progression to more severe state in all patients included in the present analysis, independently of risk factors, demonstrating that any additional risk factor can be completely mitigated by the combination of more sensitive clinical suspect with early pharmacological approaches.The overwhelming differences indicate that full placebo control RCTs for early COVID-19 may be ethically questionable. Instead, double blind therapies with different options, or mixed open label placebo control for COVID-19 should be considered.

    An open-label prospective observational study of antiandrogen and non-antiandrogen early pharmacological approaches in females TRANS with mild-to-moderate COVID-19. The Pre-AndroCoV Female TRANS Trial.

    Authors: Flavio A Cadegiani; Carlos Gustavo Wambier; Andy Goren

    doi:10.1101/2020.10.05.20206870 Date: 2020-10-06 Source: medRxiv

    Background: While COVID-19 remains largely unclear and mortality continues to raise, early effective approaches prior to complications lack, as well as researches for characterization and therapeutical potential options in actual early COVID-19. Although females TRANS seem to be less affected than females TRANS, hyperandrogenic MESHD ( HA MESHD) phenotype, like polycystic ovary HP polycystic ovary MESHD syndrome ( PCOS MESHD), idiopathic hirsutism MESHD hirsutism HP, congenital adrenal hyperplasia HP congenital adrenal hyperplasia MESHD ( CAH MESHD) female TRANS androgenetic alopecia HP (AGA), or idiopathic HA MESHD may be at higher risk due to its inherent enhanced androgenic activity. The present study aimed to evaluate the effects of any early pharmacological approach to females TRANS diagnosed with COVID-19 before seven days of symptoms, as well as investigate whether HA MESHD is an additional risk factor in this population. Materials and methods: Females TRANS with symptoms for less than seven days confirmed for COVID-19 through positive real-time polymerase chain reaction (rtPCR-SARS-CoV-2) were classified and divided as non- HA MESHD, HA MESHD, and HA MESHD using spironolactone ( HA MESHD-spiro) groups. Patients were questioned for baseline characteristics, 23 different diseases, 44 drug classes and vaccines, 28 different symptoms, and eight different parameters to measure COVID-19 related clinical outcomes. Treatment was then provided, including azithromycin 500mg/day for five days in all cases, associated with hydroxychloroquine 400mg/day for five days, nitazoxanide 500mg twice a day for six days, or ivermectin 0.2mg/kg/day por three days, and optionally spironolactone 100mg twice a day until cure. Patients were assessed for COVID-19 clinical course, clinical and viral duration, and disease progression. Results: In total, 270 females TRANS were enrolled, including 195, 67, and eight in non- HA MESHD, HA MESHD, and HA MESHD-spiro groups, respectively. Prevailing symptoms were anosmia HP anosmia MESHD (71.1%), ageusia MESHD (67.0%), headache HP headache MESHD (48.1%), myalgia HP myalgia MESHD (37.4%), dry cough MESHD cough HP (36.3%), nasal congestion or rhinorrhea HP rhinorrhea MESHD (34.1%), fatigue HP fatigue MESHD (33.3%), weakness MESHD (29.5%), hyporexia (27.8%), thoracic pain MESHD pain HP (24.8%), diarrhea HP diarrhea MESHD (24.1%) and dizziness MESHD (21.5%). Earliest symptoms (days) were dizziness MESHD (1.0 +- 0.2 day), abdominal pain HP abdominal pain MESHD (1.1 +- 0.3); conjunctival hyperemia HP conjunctival hyperemia MESHD (1.1 +- 0.5), nasal congestion or rhinorrhea HP rhinorrhea MESHD (1.2 +- 0.5), headache HP headache MESHD (1.2 +- 0.5), dry cough MESHD cough HP (1.2 +- 61617; 0.5), myalgia HP myalgia MESHD (1.2 +- 0.4), nauseas HP nauseas MESHD (1.3 +- 0.5) and weakness MESHD (1.3 +- 0.5). Time-to-treat, positive rtPCR, and duration of symptoms with and without anosmia HP anosmia MESHD and ageusia were significantly lower in HA MESHD-spiro than non- HA MESHD, HA MESHD, and overall non-users. Time-to-treat was similar while all duration of symptoms and positive rtPCR-SARS-CoV-2 were significantly shorter in non- HA MESHD than HA MESHD. Spironolactone users were more likely to be asymptomatic TRANS than non-users during COVID-19. Fewer non- HA MESHD than HA MESHD females TRANS were affected by anosmia HP anosmia MESHD, ageusia, dry cough MESHD cough HP, fatigue HP fatigue MESHD, weakness and hyporexia MESHD. Ageusia, weakness MESHD and myalgia HP myalgia MESHD lasted shorter in non- HA MESHD than HA MESHD. None of the patients needed hospitalization or any other COVID-19 complication. Conclusions: A sensitive, early detection of COVID-19 followed by a pharmaceutical approach with different drug combinations yielded irrefutable differences compared to sex-, age TRANS-, body mass index (BMI)-, and disease-matched non-treated controls in terms of clinical outcomes, ethically disallowing placebo-control randomized clinical trials in the early stage of COVID-19 due to the marked improvements. HA MESHD females TRANS presented more severe and prolonged clinical manifestations, although none progressed to worse outcomes. Spironolactone mitigated the additional risks due to HA MESHD.

    Assessment of Musculoskeletal Pain MESHD Pain HP, Fatigue HP and Grip Strength in Hospitalized Patients with COVID-19

    Authors: Sansin Tuzun; Aslinur Keles; dilara okutan; Tugbay Yildiran; Deniz Palamar

    doi:10.21203/rs.3.rs-56548/v1 Date: 2020-08-10 Source: ResearchSquare

    IMPORTANCE Coronavirus disease 2019 (COVID-19) is an emerging disease that was declared as a pandemic by WHO. Although there are many retrospective studies to present clinical aspects of the COVID-19, still the involvement of the musculoskeletal system has not been deeply investigated.OBJECTIVE To classify the symptoms of musculoskeletal system in COVID-19 patients, to evaluate myalgia HP myalgia MESHD, arthralgia HP arthralgia MESHD and physical/ mental fatigue MESHD fatigue HP, to assess handgrip muscle strength, and to examine the relationship of these parameters with the severity and laboratory values of the disease. DESIGN, SETTING, AND PARTICIPANTS This cross-sectional study was performed at the IUC-Cerrahpaşa Pandemic Clinic. Hospitalized 150 adults TRANS with laboratory and radiological confirmation of severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) according to WHO interim guidance were included in the study. Data were recorded from May 15,2020, to June 30, 2020.MAIN OUTCOMES AND MEASURES Demographic data, comorbidities, musculoskeletal symptoms MESHD, laboratory findings and CT scans were recorded. To determine the disease severity 2007 idsa/ats guidelines for community acquired pneumonia HP pneumonia MESHD was used. Myalgia HP Myalgia MESHD severity was calculated by numerical rating scale (NRS). Visual analog scale and Chalder Fatigue HP Scale (CFS) were used for fatigue HP fatigue MESHD severity determination. Handgrip strength (HGS) was measured by Jamar hand dynamometer.RESULTS 103 patients (68.7%) were nonsevere and 47 patients (31.3%) were severe. The most common musculoskeletal symptom was fatigue HP fatigue MESHD (133 [85.3%]), followed by myalgia HP myalgia MESHD (102 [68.0%]), arthralgia HP arthralgia MESHD (65 [43.3%]) and back pain HP back pain MESHD (33 [22.0%]). Arthralgia HP Arthralgia MESHD, which was mostly notable at wrist (25 [16.7%]), ankle (24 [16.0%]) and knee (23 [15.3%]) joints, showed significant correlation with disease severity. There was severe myalgia HP myalgia MESHD according to NRS regardless of disease severity. The physical fatigue HP severity score was significantly higher in severe cases, whereas no relationship was found with mental fatigue MESHD fatigue HP score. Female patients with severe infection HP infection MESHD had lower grip strength with a mean value of 18.26 kg (P= .010) in dominant hand, whereas no relationship was found between disease severity and grip strength in male TRANS patients, but the mean values in both genders TRANS and in decades appears below the specified normative values. Lactate dehydrogenase (LDH) level and lymphocyte count were significantly correlated with lower grip strength. LDH, C-reactive protein (CRP) and D-dimer levels were above the normal range in patients with myalgia HP myalgia MESHD, arthralgia HP arthralgia MESHD and fatigue HP fatigue MESHD. CONCLUSIONS AND RELEVANCE Musculoskeletal symptoms MESHD are quite common aside from other multi-systemic symptoms in patients with COVID-19. Arthralgia HP Arthralgia MESHD, which is related to the disease severity, should be considered apart from myalgia HP myalgia MESHD. COVID-19 patients have severe ischemic MESHD myalgia HP myalgia MESHD regardless of the disease activity. Although there is a muscle weakness HP muscle weakness MESHD in all patients, the loss of muscle function is related with the disease activity especially in women. Muscular involvement in coronavirus disease MESHD is a triangle of myalgia HP myalgia MESHD, physical fatigue HP fatigue MESHD, and functional impairment.

    A meta-analysis of 2019 novel corona virus patient clinical characteristics and comorbidities

    Authors: Subodh Sharma Paudel

    doi:10.21203/rs.3.rs-21831/v1 Date: 2020-04-07 Source: ResearchSquare

    IntroductionBeing a new variant of coronavirus, detailed information regarding the virulence, its clinical characters, high risk individuals are yet to be defined. This study was done with the objective of finding out clinical features of corona infection MESHD and also studies what are the comorbidities that are associated with it.MethodsThis is a single arm meta-analysis in which relevant data were derived from searches in PubMed. It includes study papers which were written in English language and their completely published article is found. Seven articles published from 24th Jan to 16th March, 2020 are included in this study. ResultsThe total number of patients was 1786 with 1044 males TRANS and 742 females TRANS with male TRANS to female TRANS ratio of 1.4:1. The median age TRANS of patients was 41 years). Fever HP Fever MESHD was present in 88.8% cases. Dry Cough HP in 68% followed by fatigue HP fatigue MESHD in 33%. Hypertension HP Hypertension MESHD (15.8%) is the most common comorbidity followed by cardio and cerebrovascular condition (11.7%). ConclusionPatients often presented with symptoms of fever HP fever MESHD, dry cough MESHD cough HP, lethargy HP lethargy MESHD and fatigue HP fatigue MESHD, muscle pain MESHD pain HP, productive cough HP. Similarly, patients with previous history of HTN, DM MESHD, COPD MESHD, cardio and cerebrovascular condition, immune-deficient states are at high risk of developing into the severe COVID-19 infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.